Results for

National Institutes of Health Director Protection Act This bill specifies that the Secretary of Health and Human Services and the Director of the National Institutes of Health (NIH) may only fire a director of a national research institute or national center of the NIH on the basis of malfeasance, neglect of office, or incapacity.

National Institutes of Health Director Protection Act This bill specifies that the Secretary of Health and Human Services and the Director of the National Institutes of Health (NIH) may only fire a director of a national research institute or national center of the NIH on the basis of malfeasance, neglect of office, or incapacity.

Pediatricians Accelerate Childhood Therapies Act of 2019 or the PACT Act of 2019 This bill provides statutory authority for the Trans-National Institutes of Health (NIH) Pediatric Research Consortium to coordinate pediatric research across national health research institutions. The consortium, chaired by the director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, must develop priorities for the NIH to award research grants to early career pediatric researchers, including physician-scientists and researchers from underrepresented populations.

Pediatricians Accelerate Childhood Therapies Act of 2019 or the PACT Act of 2019 This bill provides statutory authority for the Trans-National Institutes of Health (NIH) Pediatric Research Consortium to coordinate pediatric research across national health research institutions. The consortium, chaired by the director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, must develop priorities for the NIH to award research grants to early career pediatric researchers, including physician-scientists and researchers from underrepresented populations.

Innovation Network and Capital Act of 2019 This bill establishes and provides funds through FY2025 for a grant program in the National Institutes of Health (NIH) to expand the commercialization of biomedical products. NIH shall award grants or contracts to entities that have received funding from either the Small Business Innovation Research Program or the Small Business Technology Transfer Program of NIH. Awardees must use the funds to support participation in specified NIH programs and activities related to the commercialization stage of research, later stage research and development, technology transfer, and commercialization technical assistance.

Humane and Existing Alternatives in Research and Testing Sciences Act of 2019or the HEARTS Act of 2019 This bill directs the National Institutes of Health (NIH) to promote nonanimal research methods. Specifically, NIH must (1) provide incentives for nonanimal research and (2) require the evaluation of viable nonanimal methods before approving animal-based research. Additionally, NIH applications for research grants must include (1) harm-benefit analyses for animal-based research proposals and (2) assurance that nonanimal methods for such research are not available.

Ensuring Understanding of COVID-19 to Protect Public Health Act This bill requires the National Institutes of Health (NIH), in consultation with the Centers for Disease Control and Prevention, to conduct a longitudinal study on the health impacts of COVID-19 (i.e., coronavirus disease 2019). The NIH must provide public summaries of findings on specified timelines.

Ensuring Understanding of COVID-19 to Protect Public Health Act This bill requires the National Institutes of Health (NIH), in consultation with the Centers for Disease Control and Prevention, to conduct a longitudinal study on the health impacts of COVID-19 (i.e., coronavirus disease 2019). The NIH must provide public summaries of findings on specified timelines.

National Institute for Research on Safety and Quality Act This bill establishes the National Institute for Research on Safety and Quality within the National Institutes of Health and transfers the authorities, duties, obligations, and related legal and administrative functions of the Agency for Healthcare Research and Quality to that institute. In addition, the new institute must promote health care quality improvement and conduct research and demonstration projects focused on (1) the delivery of health care in inner cities and rural and frontier areas, and (2) health care for priority populations such as low-income groups and the elderly.

National Biomedical Research Act This bill establishes and makes deposits into the Biomedical Innovation Fund for initiatives at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) for advancing medical innovation, including by supporting (1) research for disease prevention, diagnosis, and treatment; (2) research for diseases that disproportionally account for federal health care spending; (3) the development, review, and post-market surveillance of medical products; (4) early-career scientists, including researchers from traditionally underrepresented groups; and (5) other innovative research. The bill also requries annual reporting about the fund by the NIH, the FDA, and the Department of the Treasury.

Expanding Cannabis Research and Information Act This bill changes marijuana from a Schedule I to a Schedule III controlled substance, which allows it to be dispensed, subject to certain limitations, for accepted medical uses with a written or oral prescription. The bill also requires the National Institutes of Health (NIH) to collaborate with specified agencies to develop a national cannabis research agenda that must address (1) the therapeutic benefits of cannabis, (2) how it effects specified populations, (3) its long-term effects, (4) clinically appropriate methods to deliver it to the body, and (5) other public safety considerations. Additionally, the bill directs NIH to designate centers of excellence in cannabis research at institutions of higher education to conduct interdisciplinary research about biomedical, behavioral, and social issued related to cannabis. Further, the Centers for Disease Control and Prevention must work with other agencies to collect population-wide data about cannabis use, including (1) demographic factors, (2) health outcomes, (3) health care utilization rates, (4) product variety, (5) delivery methods, and (6) other relevant health information.

Expanding Cannabis Research and Information Act This bill changes marijuana from a Schedule I to a Schedule III controlled substance, which allows it to be dispensed, subject to certain limitations, for accepted medical uses with a written or oral prescription. The bill also requires the National Institutes of Health (NIH) to collaborate with specified agencies to develop a national cannabis research agenda that must address (1) the therapeutic benefits of cannabis, (2) how it effects specified populations, (3) its long-term effects, (4) clinically appropriate methods to deliver it to the body, and (5) other public safety considerations. Additionally, the bill directs NIH to designate centers of excellence in cannabis research at institutions of higher education to conduct interdisciplinary research about biomedical, behavioral, and social issued related to cannabis. Further, the Centers for Disease Control and Prevention must work with other agencies to collect population-wide data about cannabis use, including (1) demographic factors, (2) health outcomes, (3) health care utilization rates, (4) product variety, (5) delivery methods, and (6) other relevant health information.

National Commission on Scleroderma and Fibrotic Diseases Act of2019 This bill temporarily establishes a National Commission on Fibrotic Diseases within the National Institutes of Health that must recommend improvements regarding fibrosis and fibrotic disease research.

National Commission on Scleroderma and Fibrotic Diseases Act of2019 This bill temporarily establishes a National Commission on Fibrotic Diseases within the National Institutes of Health that must recommend improvements regarding fibrosis and fibrotic disease research.

Collaborative Academic Research Efforts for Tourette Syndrome Act of2019 This bill requires the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH research on Tourette syndrome. The NIH must (1) develop a system to collect data on Tourette syndrome, including epidemiological information and data on the availability of medical and social services for individuals with Tourette syndrome and their families; (2) support Collaborative Research Centers for Tourette Syndrome to conduct basic and clinical research; (3) award grants for research on Tourette syndrome symptoms and treatment options for particular patient subpopulations; and (4) designate funding to carry out Tourette syndrome programs and activities.

Collaborative Academic Research Efforts for Tourette Syndrome Act of2020 or the CARE for Tourette Syndrome Act of 2020 This bill requires the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH research on Tourette syndrome. The NIH must (1) develop a system to collect data on Tourette syndrome, including epidemiological information and data on the availability of medical and social services for individuals with Tourette syndrome and their families; (2) support Collaborative Research Centers for Tourette Syndrome to conduct basic and clinical research; (3) award grants for research on Tourette syndrome symptoms and treatment options for particular patient subpopulations; and (4) designate funding to carry out Tourette syndrome programs and activities.

Jonny Wade Pediatric Cancer Research Act This bill terminates (1) the taxpayer election to designate $3 of income tax liability for financing of presidential election campaigns, (2) the Presidential Election Campaign Fund, and (3) the Presidential Primary Matching Payment Account. The Department of the Treasury must transfer the funds remaining in the Presidential Election Campaign Fund to the 10-Year Pediatric Research Initiative Fund. The National Institutes of Health (NIH) must prioritize certain pediatric research that does not replicate existing NIH research activities.

Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2019 or the CCM-CARE Act This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.) The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients. The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation. The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways.

Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2019 or the CCM-CARE Act This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.) The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients. The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation. The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways.

Patients First Act of2019 This bill requires the National Institutes of Health (NIH) to support stem cell research. Specifically, the NIH must conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions. However, such techniques must not involve (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this bill. The NIH must also report on peer-reviewed stem cell research proposals that were not funded.

Patients First Act of2019 This bill requires the National Institutes of Health (NIH) to support stem cell research. Specifically, the NIH must conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions. However, such techniques must not involve (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this bill. The NIH must also report on peer-reviewed stem cell research proposals that were not funded.

National Institute of Nutrition Act This bill establishes the National Institute of Nutrition within the National Institutes of Health to research the relationship between nutrients, food, and health outcomes.